Front Page News

Majority of Children with SMA Treated with Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate

October 17, 2024
Posted in , ,

Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before 6 weeks of age, with most achieving motor milestones similar to children […]

Read More ›

Cure SMA Hosting Puerto Rico Summit of Strength & Walk-N-Roll

October 16, 2024
Posted in ,

Cure SMA is thrilled to announce the 2025 San Juan, Puerto Rico Summit of Strength,taking place on Saturday, February 1. The Summit of Strength is a […]

Read More ›

Cure SMA is Thrilled to Launch New Travel Resources Webpage and a New Travel Support Package

October 14, 2024
Posted in ,

Along with funding SMA research and care, Cure SMA provides thousands of individuals and families with vital support and resources that help people navigate life […]

Read More ›

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

October 8, 2024
Posted in , ,

Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in […]

Read More ›

Scholar Rock Announces Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)

October 7, 2024
Posted in , ,

Today, Scholar Rock announced plans to submit a U.S. Biologics License Application (BLA) and a European Union marketing authorisation application (MAA) in Q1 2025. Scholar […]

Read More ›

Celebrating Disability Pride and the 34th Anniversary of the ADA at the White House

September 11, 2024
Posted in ,

This week, Cure SMA and advocates with SMA celebrated Disability Pride and the 34th Anniversary of the Americans with Disabilities Act (ADA) with a special […]

Read More ›

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 4, 2024
Posted in ,

The positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the treatment of SMA.  Biogen plans to submit for regulatory approval […]

Read More ›

Community Spotlight: Viola Dwyer, SMA Community Advocate from Pennsylvania

August 27, 2024
Posted in ,

During this SMA Awareness Month, Cure SMA recognizes all SMA community advocates – individuals with spinal muscular atrophy (SMA) and their families – who are […]

Read More ›

Cure SMA Attends Spring 2024 Professional Organization Conferences to Promote Findings from Real World Evidence Collaboration Initiatives

August 13, 2024
Posted in ,

Cure SMA is pleased to announce the involvement of scientific leadership, in the 4th Scientific International Congress on SMA (March 14 – 16, 2024), the […]

Read More ›

Cure SMA Launches Request for Proposals for SMA Research Projects and Postdoctoral Fellowships

August 2, 2024
Posted in ,

Earlier this summer, at the Annual SMA Research and Clinical Care Meeting, Cure SMA highlighted six new basic research grants totalling $750,000. Cure SMA is […]

Read More ›
Scroll to Top